Lanean...
Synergy between PPARγ Ligands and Platinum-Based Drugs in Cancer
PPARγ is a member of the nuclear receptor family for which agonist ligands have antigrowth effects. However, clinical studies using PPARγ ligands as a monotherapy failed to show a beneficial effect. Here we have studied the effects of PPARγ activation with chemotherapeutic agents in current use for...
Gorde:
| Egile Nagusiak: | , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2007
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2564847/ https://ncbi.nlm.nih.gov/pubmed/17482130 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccr.2007.02.025 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|